Erratum: Remdesivir for severe covid-19: A clinical practice guideline ((BMJ (2020) 370 (m2924) DOI: 10.1136/bmj.m2924);Remdesivir for severe covid-19: A clinical practice guideline

The BMJ

Volumn 370, Issue , 2020, Pages

  Rochwerg, Bram ^a   Agarwal, Arnav ^a,b   Zeng, Linan ^a,c   Leo, Yee Sin ^d   Appiah, John Adabie ^e   Agoritsas, Thomas ^a,f   Bartoszko, Jessica ^a   Brignardello Petersen, Romina ^a   Ergan, Begum ^g   Ge, Long ^a,h   Geduld, Heike ⁱ   Gershengorn, Hayley B ^j,k   Manai, Hela ^l   Huang, Minhua ^m   Lamontagne, François ⁿ   Kanda, Seema ^a   Kawano Dourado, Leticia ^o,p   Kurian, Linda ^q   Kwizera, Arthur ^r   Murthy, Srinivas ^s   Qadir, Nida ^t   Siemieniuk, Reed ^a   Silvestre, Maria Asuncion ^u,v   Vandvik, Per Olav ^w   Ye, Zhikang ^a   Zeraatkar, Dena ^a   Guyatt, Gordon ^a,j   more..

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SICHUAN UNIVERSITY   (China)

^d NATIONAL CENTRE FOR INFECTIOUS DISEASES   (Singapore)

^e KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g DOKUZ EYLUL UNIVERSITY   (Turkey)

^h LANZHOU UNIVERSITY   (China)

ⁱ UNIVERSITY OF STELLENBOSCH   (South Africa)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^l UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

^m Guangdong Rocent Information Technology Co Ltd   (China)

ⁿ CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^o UNIVERSITY OF SÃO PAULO   (Brazil)

^p Associacao Beneficente Siria   (Brazil)

^q DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^r MAKERERE UNIVERSITY   (Uganda)

^s UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u Kalusugan Ng Mag Ina (Health of Mother and Child) Inc   (Philippines)

^v Asia Pacific Center for Evidence Based Healthcare   (Philippines)

^w UNIVERSITY OF OSLO   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; OXYGEN; PLACEBO; REMDESIVIR; ADENOSINE PHOSPHATE; ALANINE; ANTIVIRUS AGENT;

ARTICLE; ARTIFICIAL VENTILATION; BREATHING RATE; CLINICAL PRACTICE; CORONAVIRUS DISEASE 2019; DISEASE SEVERITY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; HUMAN; HYPERGLYCEMIA; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LENGTH OF STAY; LIVER DYSFUNCTION; MEDICAL DECISION MAKING; MORTALITY; OXYGEN SATURATION; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; UNITED STATES; BETACORONAVIRUS; CORONAVIRUS INFECTION; ISOLATION AND PURIFICATION; NETWORK META-ANALYSIS; PANDEMIC; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; TIME FACTOR; VIROLOGY; VIRUS PNEUMONIA;

ADENOSINE MONOPHOSPHATE; ALANINE; ANTIVIRAL AGENTS; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; GUIDELINE ADHERENCE; HUMANS; LENGTH OF STAY; NETWORK META-ANALYSIS; PANDEMICS; PNEUMONIA, VIRAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATION, ARTIFICIAL; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 85088885703     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.m4542     Document Type: Erratum

References (22)

1. Johns Hopkins University. COVID-19 dashboard. 2020. https://coronavirus.jhu.edu/map.html.
2. Alhazzani W, Moller MH, Arabi YM, etal. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med 2020;48:e440-69. doi: 10.1097/CCM.0000000000004363 pmid: 32224769
3. Ye Z, Rochwerg B, Wang Y, etal. Treatment of patients with nonsevere and severe coronavirus disease 2019: An evidence-based guideline. CMAJ 2020;192:E536-45. doi: 10.1503/cmaj.200648 pmid: 32350002
4. Bhimraj A, Morgan RL, Shumaker AH, etal. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis 2020;. doi: 10.1093/cid/ciaa478 pmid: 32338708
5. Ye W, Yao M, Dong Y, etal. Remdesivir (GS-5734) impedes enterovirus replication through viral RNA synthesis inhibition. Front Microbiol 2020;11:1105. doi: 10.3389/fmicb.2020.01105 pmid: 32595613
6. UpToDate. Coronavirus disease 2019 (COVID-19): management in hospitalized adults. 2020. https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-management-in-hospitalized-Adults.
7. National Institutes of Health. COVID-19 treatment guidelines. 2020. https://www.covid19treatmentguidelines. nih.gov/whats-new/.
8. Beigel JH, Tomashek KM, Dodd LE, etal. Remdesivir for the treatment of Covid-19-preliminary report. N Engl J Med 2020; doi: 10.1056/NEJMoa2007764.
9. Siemieniuk RA, Agoritsas T, Macdonald H, Guyatt GH, Brandt L, Vandvik PO. Introduction to BMJ Rapid Recommendations. BMJ 2016;354:i5191. doi: 10.1136/bmj.i5191 pmid: 27680768
10. Siemieniuk RAC, Bartoszko JJ, Ge L, etal. Drug treatments for covid-19: living systematic review and network meta-Analysis. BMJ 2020;370:m2980, doi: 10.1136/bmj.m2980
11. Wang Y, Zhang D, Du G, etal. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:1569-78. doi: 10.1016/S0140-6736(20)31022-9 pmid: 32423584
12. Vandvik PO, Otto CM, Siemieniuk RA, etal. Transcatheter or surgical aortic valve replacement for patients with severe, symptomatic, aortic stenosis at low to intermediate surgical risk: A clinical practice guideline. BMJ 2016;354:i5085. doi: 10.1136/bmj.i5085 pmid: 27680583
13. Guyatt GH, Oxman AD, Vist GE, etalGRADE Working Group. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6. doi: 10.1136/bmj.39489.470347.AD pmid: 18436948
14. Andrews JC, Schönemann HJ, Oxman AD, etal. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation?s direction and strength. J Clin Epidemiol 2013;66:726-35. doi: 10.1016/j.jclinepi.2013.02.003 pmid: 23570745
15. Docherty AB, Harrison EM, Green CA, etalISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020;369:m1985. doi: 10.1136/bmj.m1985 pmid: 32444460
16. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty?JAMA 2003;289:2554-9. doi: 10.1001/jama.289.19.2554 pmid: 12759327
17. Ferreira-González I, Busse JW, Heels-Ansdell D, etal. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007;334:786. doi: 10.1136/bmj.39136.682083.AE pmid: 17403713
18. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009;169:1756-61. doi: 10.1001/archinternmed.2009.306 pmid: 19858432
19. World Health Organization. Clinical management of COVID-19: interim guidance. 2020. https://www.who.int/publications/i/item/clinical-management-of-covid-19.
20. Goldman JD, Lye DCB, Hui DS, etalGS-US-540-5773 Investigators. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020; doi: 10.1056/NEJMoa2015301 pmid: 32459919
21. Maguire BJ, Guérin PJ. A living systematic review protocol for COVID-19 clinical trial registrations. Wellcome Open Res 2020;5:60. doi: 10.12688/wellcomeopenres.15821.1 pmid: 32292826
22. Infectious Diseases Data Observatory. Living systematic review COVID-19. 2020. https://www.iddo.org/research-Themes/covid-19/live-systematic-clinical-Trial-review